Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.
Employees: 11-50
Total raised: $75M
Investors 3
| Date | Name | Website |
| 22.06.2023 | Avego | avego.com |
| 25.07.2023 | TCG Crosso... | tcgcrossov... |
| 25.03.2024 | Longitude ... | longitudec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.10.2023 | - | $75M | - |
Mentions in press and media 2
| Date | Title | Description |
| 13.06.2024 | The Lustgarten Foundation Appoints Two New Board Members | To date, the foundation has invested more than $282M in high-risk, high-reward research to accelerate and expand life-saving treatment options. Richard Barakat, MD, and Aaron Kantoff join the Lustgarten Foundation Board of Directors WOODBUR... |
| 19.10.2023 | Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million | - |